Health ❯ Healthcare ❯ Pharmaceuticals ❯ Weight Loss

Orforglipron

FDA Clears Eli Lilly’s Foundayo Oral GLP-1 for Weight Loss, With U.S. Launch Set for April 6

The move positions Lilly to challenge Novo Nordisk by pairing a more flexible pill with a rapid LillyDirect rollout and aggressive self-pay pricing.

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study

Lilly’s Oral GLP-1 Pill Underperforms Wegovy in Late-Stage Trial